Brokerages Set Coya Therapeutics, Inc. (NASDAQ:COYA) Target Price at $16.00

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $16.00.

Several research analysts recently issued reports on COYA shares. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, March 23rd. Wall Street Zen raised shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. D. Boral Capital reissued a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a research report on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Finally, Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th.

Coya Therapeutics Stock Performance

Shares of COYA opened at $4.99 on Friday. The company has a 50-day simple moving average of $4.53 and a 200-day simple moving average of $5.28. The firm has a market capitalization of $117.07 million, a P/E ratio of -3.93 and a beta of 0.51. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million. As a group, equities analysts forecast that Coya Therapeutics will post -1.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. acquired a new position in Coya Therapeutics in the third quarter worth about $28,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth approximately $47,000. Occudo Quantitative Strategies LP acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth approximately $66,000. Lantern Wealth Advisors LLC acquired a new stake in shares of Coya Therapeutics during the third quarter worth approximately $66,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in shares of Coya Therapeutics during the fourth quarter worth approximately $81,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.